Synonym:RC1291;RC1291;RC-1291;RC1291HCl;ONO7643;ONO-7643;ONO7643;AnamorelinHCl

IUPAC/ChemicalName:2-amino-N-((R)-1-((R)-3-benzyl-3-(1,2,2-trimethylhydrazinecarbonyl)piperidin-1-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-2-methylpropanamidehydrochloride

InChiKey:VFYAEUWJFGTGGO-GHTUPXNNSA-N

InChiCode:InChI=1S/C31H42N6O3.ClH/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22;/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39);1H/t26-,31-;/m1./s1

SMILESCode:CC(C)(N)C(N[C@H](CC1=CNC2=C1C=CC=C2)C(N3C[C@](C(N(C)N(C)C)=O)(CC4=CC=CC=C4)CCC3)=O)=O.[H]Cl.

TechnicalData

AdditionalInformation

Related:
861998-00-7(AnamorelinHClsalt)
249921-19-5(Anamorelinfreebase)

References

1:ZhangH,GarciaJM.Anamorelinhydrochlorideforthetreatmentofcancer-anorexia-cachexiainNSCLC.ExpertOpinPharmacother.2015Jun;16(8):1245-53.doi:10.1517/14656566.2015.1041500.Epub2015May6.PubMedPMID:25945893.

2:vonHaehlingS,AnkerSD.Treatmentofcachexia:Anoverviewofrecentdevelopments.IntJCardiol.2015Apr1;184:736-42.doi:10.1016/j.ijcard.2014.10.026.Epub2014Oct16.PubMedPMID:25804188.

3:BaracosVE.Skeletalmuscleanabolisminpatientswithadvancedcancer.LancetOncol.2015Jan;16(1):13-4.doi:10.1016/S1470-2045(14)71185-4.Epub2014Dec16.PubMedPMID:25524803.

4:GarciaJM,BocciaRV,GrahamCD,YanY,DuusEM,AllenS,FriendJ.Anamorelinforpatientswithcancercachexia:anintegratedanalysisoftwophase2,randomised,placebo-controlled,double-blindtrials.LancetOncol.2015Jan;16(1):108-16.doi:10.1016/S1470-2045(14)71154-4.Epub2014Dec16.PubMedPMID:25524795.

5:vonHaehlingS,AnkerSD.Treatmentofcachexia:anoverviewofrecentdevelopments.JAmMedDirAssoc.2014Dec;15(12):866-72.doi:10.1016/j.jamda.2014.09.007.Epub2014Nov20.PubMedPMID:25455531.

6:vonHaehlingS,AnkerSD.Prevalence,incidenceandclinicalimpactofcachexia:factsandnumbers-update2014.JCachexiaSarcopeniaMuscle.2014Dec;5(4):261-3.doi:10.1007/s13539-014-0164-8.PubMedPMID:25384990;PubMedCentralPMCID:PMC4248411.

7:SalsmanJM,BeaumontJL,WortmanK,YanY,FriendJ,CellaD.BriefversionsoftheFACIT-fatigueandFAACTsubscalesforpatientswithnon-smallcelllungcancercachexia.SupportCareCancer.2015May;23(5):1355-64.doi:10.1007/s00520-014-2484-9.Epub2014Oct29.PubMedPMID:25351456;PubMedCentralPMCID:PMC4376952.

8:PietraC,TakedaY,Tazawa-OgataN,MinamiM,YuanfengX,DuusEM,NorthrupR.AnamorelinHCl(ONO-7643),anovelghrelinreceptoragoNIST,forthetreatmentofcanceranorexia-cachexiasyndrome:preclinicalprofile.JCachexiaSarcopeniaMuscle.2014Dec;5(4):329-37.doi:10.1007/s13539-014-0159-5.Epub2014Sep30.PubMedPMID:25267366;PubMedCentralPMCID:PMC4248409.

9:EbnerN,SteinbeckL,DoehnerW,AnkerSD,vonHaehlingS.Highlightsfromthe7thCachexiaConference:musclewastingpathophysiologicaldetectionandnoveltreatmentstrategies.JCachexiaSarcopeniaMuscle.2014Mar;5(1):27-34.doi:10.1007/s13539-014-0136-z.Epub2014Mar5.PubMedPMID:24595460;PubMedCentralPMCID:PMC3953317.

10:CurrowDC,AbernethyAP.Anamorelinhydrochlorideinthetreatmentofcanceranorexia-cachexiasyndrome.FutureOncol.2014Apr;10(5):789-802.doi:10.2217/fon.14.14.Epub2014Jan28.PubMedPMID:24472001.